-
2023-503220-76-01
6
2024-02-13
Unexplained recurrent miscarriages
-
2023-508029-28-00
6
2024-02-13
Eosinophilic Granulomatosis with Polyangiitis (eGPA)
-
2023-506698-36-00
5
2024-02-02
low-volume metastatic castration-sensitive prostate cancer
-
2023-505287-11-01
3
2024-02-01
Critical limb ischemia
-
2023-503327-26-00
5
2024-01-31
Sjogren's syndrome
-
2023-509142-35-00
6
2024-01-29
Atrial fibrillation after stress (e.g., noncardiac surgery or acute me
-
2023-506971-89-00
5
2024-01-25
Coronary Artery Disease
-
2023-509158-68-00
1
2024-01-25
Parkinson’s disease
-
2023-508543-42-00
1
2024-01-22
Chronic heart failure
-
2023-505379-61-00
4
2024-01-17
Acute Myeloid Leukaemia
-
2022-502685-25-00
10
2024-01-01
The trial population will consist of patients with LAVC who require pr
-
2023-503462-23-00
5
2023-12-28
Lung transplant rejection
-
2023-504637-42-01
6
2023-12-21
aortic valve stenosis
-
2024-516736-10-00
4
2023-12-18
Mismatch repair deficient endometrial cancer / uterine cancer
-
2023-503533-21-00
4
2023-11-21
Low-grade serous ovarian cancer
-
2023-503582-35-00
6
2023-10-26
Staphylococcus aureus bacteremia
-
2023-503661-28-00
5
2023-10-26
Hidradenitis Suppurativa
-
2022-502160-20-00
5
2023-10-02
Idiopathic Immune Complex Mediated Membranoproliferative Glomeruloneph
-
2022-501831-18-00
4
2023-09-13
Patients with hematologic malignancies and undergoing allogenic hemato
-
2023-504709-35-00
1
2023-08-16
Locally advanced or metastatic solid tumors
-
2022-503133-54-00
7
2023-08-09
Solid Tumors
-
2022-501797-19-00
1
2023-07-13
Acute Myeloid Leukemia (AML)
-
2022-502703-30-00
6
2023-06-28
neuroendocrine tumours
-
2022-501620-26-00
6
2023-05-15
prosthetic joint infection